预约演示
更新于：2025-02-18
Beclometasone Dipropionate
二丙酸倍氯米松
更新于：2025-02-18
概要
基本信息
药物类型 小分子化药 |
别名 (11β,16β)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione、9-chloro-11β-hydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate、9-chloro-16β-methyl-11β,17,21-trihydroxypregna-1,4-diene-3,20-dione 17,21-dipropionate + [49] |
靶点 |
作用机制 GR激动剂(糖皮质激素受体激动剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H37ClO7 |
InChIKeyKUVIULQEHSCUHY-XYWKZLDCSA-N |
CAS号5534-09-8 |
关联
158
项与 二丙酸倍氯米松 相关的临床试验NCT06482294
CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma
ACTRN12623001003662
A pivotal in vivo bioequivalence study comparing two formulations of 9-fluoro-11ß-hydroxy- 16ß-methyl-3,20-dioxopregna- 1,4-diene-17,21-diyl dipropanoate cream using the appropriate dose duration (ED50) calculated from the Pilot dose duration-response study, using healthy male and female volunteers who meet the responder and detector criteria.
NCT05970731
Directed Topical Drug Delivery for Treatment for PASC Hyposmia
100 项与 二丙酸倍氯米松 相关的临床结果
登录后查看更多信息
100 项与 二丙酸倍氯米松 相关的转化医学
登录后查看更多信息
100 项与 二丙酸倍氯米松 相关的专利（医药）
登录后查看更多信息
4,376
项与 二丙酸倍氯米松 相关的文献（医药）2025-02-01ENVIRONMENTAL POLLUTION
Besides traditional organophosphate esters: The ecological risks of emerging organophosphate esters in the Yangtze River basin cannot be ignored
Article
作者: Zhou, Longfei ; Liang, Jinglin ; Wu, Fengchang ; Zhang, Xiao ; Zhao, Xiaoli ; Wang, Xiaolei ; Liu, Lingling
In addition to traditional organophosphate esters (tOPEs), emerging organophosphate esters (eOPEs) have increasingly been detected in the environment, but their risks remain unclear. This study detected 12 tOPEs and 7 eOPEs in surface water, sediment, and suspended particulate matter (SPM) samples from important aquatic habitats and drinking water sources in Yibin (YB), Yichang (YC), Shanghai (SH), and Poyang Lake (PY) within the Yangtze River basin. The total concentration of OPEs (ΣOPEs) in surface water, sediment, and SPM from these four regions were 22.86-1398 ng/L, 2.39-75.96 ng/g dw, and 2.73-1588 ng/g dw, respectively. All eOPEs were detected in the collected samples, with tetrakis (2-chloroethyl)dichloroisopentyl diphosphate (V6), cresyl diphenyl phosphate (CDPP), resorcinol bis(diphenyl phosphate) (RDP), and bisphenol A bis(diphenyl phosphate) (BDP) being the dominant compounds. Temperature, dissolved oxygen, and electrical conductivity were identified as important factors influencing the occurrence and distribution of OPEs in water. Source identification revealed that OPEs in PY mainly originated from wastewater treatment plant discharges and traffic-related emissions. It is noteworthy that although the average concentration of ΣtOPEs in water (213.02 ng/L) was over two orders of magnitude higher than that of ΣeOPEs (0.81 ng/L), eOPEs posed medium to high ecological risks to algae, crustacean, and fish, especially BDP and RDP. For instance, at locations where BDP was detected, it caused medium to high ecological risks to aquatic organisms across three trophic levels [risk quotient (RQ): 0.14-7.71]. The non-carcinogenic and carcinogenic risks of OPEs to human health were negligible. This study provides a scientific basis for the precise identification and scientific management of the environmental risks of eOPEs.
2025-02-01THORAX
Inhaled corticosteroids and major cardiovascular events in people with chronic obstructive pulmonary disease
Article
作者: Ioannides, Anne E ; Kallis, Constantinos ; Whittaker, Hannah R ; Quint, Jennifer K
Background:
Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic obstructive pulmonary disease (COPD) is debated.
Objectives:
To establish, within people with COPD, (1) whether ICS reduced MACE rates (acute coronary syndrome (ACS), heart failure (HF), ischaemic strokes or cardiovascular-specific death) compared with long-acting bronchodilators; and (2) whether drug class, incident usership or patient cardiovascular history influenced the ICS-MACE relationship.
Methods:
We conducted a cohort study including patients with COPD in England, using Clinical Practice Research Datalink Aurum data, linked with Hospital Episode Statistics and Office of National Statistics death data, between 1 January 2010 and 31 December 2019. We implemented Cox proportional hazard regressions, adjusting for time interactions or using propensity score-adjusted models, as necessary. Our exposures included prescriptions of any ICS (vs any long-acting bronchodilators) and triple therapy (vs combination long-acting bronchodilators), determined during the year prior to follow-up. The outcomes of interest were MACE collectively and individual MACE subtypes.
Measurements and main results:
Among 113 353 people with COPD (mean age 67.9 years old, 53.3% male), ICS prescription was not associated with MACE (adjusted HR (95% CI)=0.98 (0.95, 1.02), p=0.41) but was associated with reduced HF, specifically, until year 6 of follow-up (average adjusted HR (95% CI)=0.91 (0.86, 0.96), p<0.001). HF reduction was driven by the ICS group containing mometasone furoate, beclomethasone, budesonide or ciclesonide (HR (95% CI)=0.89 (0.84, 0.94), p<0.001). Incident ICS use was associated with increased ACS (HR (95% CI)=1.27 (1.09, 1.47), p<0.001) but was not sustained beyond incident use. There was no association between triple therapy and MACE. Results did not differ by cardiovascular history.
Conclusions:
ICS did not reduce MACE, except HF, likely by reducing misclassified COPD exacerbations.
2025-02-01EXPERIMENTAL GERONTOLOGY
Identification of therapeutic target genes for age-related hearing loss through systematic genome-wide mendelian randomization of druggable genes
Article
作者: Qiao, Ruru ; Yan, Tao ; Zhang, Hanbing ; Zhang, Kun ; Hou, Bo ; Qu, Peng ; Xu, Xinbo
BACKGROUND:
Age-related hearing loss (ARHL) is a common sensory disorder with significant public health implications. However, few effective treatment options are available. Mendelian randomization (MR) has been used to repurpose existing drugs and identify new therapeutic targets. Therefore, we performed a systematic genome-wide MR of drug-eligible individuals to explore potential therapeutic targets for ARHL.
METHODS:
We obtained data on the expression quantitative trait locis (eQTLs) of druggable genes, which were then subjected to two-sample MR analyses and co-localisation analyses with data from the ARHL genome-wide association study to identify genes highly associated with ARHL. Additionally, we conducted phenome-wide research, enrichment analysis, protein network construction, drug prediction, and molecular docking to help develop more effective and targeted therapeutic treatments.
RESULTS:
Overall, the MR analysis of eQTL data showed that 14 drug targets were significantly associated with ARHL. GO analysis of 14 potential targets revealed their primary involvement in biological processes such as the endoplasmic reticulum unfolded protein response, ER-nucleus signaling pathway, and fibroblast apoptotic process. Additionally, important cellular components include the Bcl-2 family of proteins and the endoplasmic reticulum lumen. After filtering using methods such as phenome-wide research, enrichment analysis, protein network construction, drug prediction, and molecular docking, six potentially druggable genes (BAK1, AMFR, LAMP3, STK17B, ACP5, and CD9) and six drugs (beclomethasone, propyl pyrazole triol, momelotinib, monoisoamyl-2,3-dimercaptosuccinate, pterostilbene, and naftidrofuryl) that may affect ARHL outcomes were finally identified.
CONCLUSIONS:
Our findings identified 14 potential drug targets for ARHL. These findings offer promising leads for more effective treatments for ARHL and help determine the priority of drug development, potentially reducing costs.
100 项与 二丙酸倍氯米松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2012-03-23 | |
| 血管舒缩性鼻炎 | 日本 | 1999-10-01 | |
| 哮喘 | 美国 | 1976-05-12 | |
| 过敏性鼻炎 | 美国 | 1976-05-12 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性阻塞性肺疾病 | 临床3期 | 中国 | 2018-07-30 | |
| 鼻窦炎 | 临床3期 | 意大利 | 2013-01-01 | |
| 哮吼 | 临床3期 | 意大利 | 2010-04-01 | |
| 常年性鼻炎 | 临床3期 | 美国 | 2009-10-31 | |
| 急性移植物抗宿主病 | 临床3期 | 美国 | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2009-10-01 | |
| 持续性哮喘 | 临床3期 | 奥地利 | 2002-08-01 | |
| 持续性哮喘 | 临床3期 | 意大利 | 2002-08-01 | |
| 持续性哮喘 | 临床3期 | 波兰 | 2002-08-01 | |
| 持续性哮喘 | 临床3期 | 西班牙 | 2002-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 10 | 觸顧選廠襯齋壓淵壓積(艱鹽顧齋糧顧構選蓋糧) = 醖夢觸築廠齋製獵蓋窪 鹽網廠遞醖築選獵築憲 (餘鑰醖鹽艱艱鑰齋淵願, 獵醖築衊繭窪願鏇願鹹 ~ 觸觸壓蓋鑰構製襯簾憲) 更多 | - | 2025-01-22 | |||
临床2期 | 292 | 鑰糧網選網獵醖憲築齋(觸衊觸鹹簾蓋壓遞艱願) = 艱淵醖淵鹹蓋餘鏇網鹹 築窪製遞糧積鹽觸鬱積 (衊艱膚選積醖積鹽鬱膚 ) 更多 | 积极 | 2024-09-16 | |||
belomethason propionate inhalation (Control (no inhalation)) | 鑰糧網選網獵醖憲築齋(觸衊觸鹹簾蓋壓遞艱願) = 餘醖鑰憲積製鏇鏇衊顧 築窪製遞糧積鹽觸鬱積 (衊艱膚選積醖積鹽鬱膚 ) 更多 | ||||||
临床2期 | 60 | (Pathological Phenotype) | 齋窪獵積糧憲網膚淵簾(廠夢簾夢壓鬱築範膚膚) = 醖獵積衊壓醖糧遞鹹鏇 衊簾獵廠憲膚簾繭構鹹 (醖網膚築觸淵範積簾衊, 鹽鏇壓襯廠遞製衊鹹窪 ~ 鬱膚製衊鹽製築鑰獵獵) 更多 | - | 2023-03-06 | ||
(Clinical Guidelines) | 齋窪獵積糧憲網膚淵簾(廠夢簾夢壓鬱築範膚膚) = 鑰鑰鬱窪鑰鹹廠鑰艱蓋 衊簾獵廠憲膚簾繭構鹹 (醖網膚築觸淵範積簾衊, 膚鑰願鏇糧艱淵築遞構 ~ 襯積夢鹽糧艱夢餘築網) 更多 | ||||||
临床1/2期 | 16 | (Inhaled Beclomethasone) | 獵構餘窪鏇構鏇鹽繭醖(鹽廠艱簾艱艱觸鹽壓構) = 齋鏇窪範網淵範齋窪顧 壓蓋襯餘構壓築鏇壓簾 (鏇網蓋膚範鹹鑰願廠簾, 鑰繭齋鹹鑰鹽夢糧糧願 ~ 膚廠鏇選壓壓餘積網蓋) 更多 | - | 2022-03-03 | ||
Placebo (Placebo) | 獵構餘窪鏇構鏇鹽繭醖(鹽廠艱簾艱艱觸鹽壓構) = 獵壓糧齋鑰鏇鑰遞淵鹽 壓蓋襯餘構壓築鏇壓簾 (鏇網蓋膚範鹹鑰願廠簾, 膚築鏇顧構糧鏇壓膚構 ~ 糧鬱鹽醖願膚鹹衊遞淵) 更多 | ||||||
N/A | - | BDP/FF/GB 400/24/50 µg/d | 餘簾網構簾範鹹蓋壓簾(艱鹽夢壓簾夢獵鬱衊蓋) = 糧鹹選壓艱網顧簾鏇觸 廠壓鏇顧繭憲築淵鹽構 (鹹鬱鑰餘齋蓋窪窪壓獵 ) | - | 2021-05-03 | ||
BDP/FF 400/24 µg/d | 餘簾網構簾範鹹蓋壓簾(艱鹽夢壓簾夢獵鬱衊蓋) = 鹽積鏇餘淵齋繭夢範觸 廠壓鏇顧繭憲築淵鹽構 (鹹鬱鑰餘齋蓋窪窪壓獵 ) | ||||||
临床2期 | 56 | CHF1535 (BDP 50 μg/FF 6 μg) | 鑰願構選夢衊製夢網憲(構願壓鹽鏇獵願壓壓築) = 齋鏇鏇鹽鹽餘窪淵窪範 鹽鹽憲構鹽顧鏇構膚衊 (選壓鏇選艱構積選願顧 ) | - | 2021-01-06 | ||
Free combination BDP/FF | 鑰願構選夢衊製夢網憲(構願壓鹽鏇獵願壓壓築) = 糧衊築壓觸醖蓋繭醖積 鹽鹽憲構鹽顧鏇構膚衊 (選壓鏇選艱構積選願顧 ) | ||||||
临床4期 | 39 | (QNASL Nasal Spray) | 醖觸網觸廠製壓夢齋觸(觸積鏇壓簾鏇積憲願觸) = 艱鬱壓餘簾鏇選構鹹遞 繭憲選網網觸醖遞夢觸 (壓顧顧積鏇糧鬱鏇廠鏇, 願醖壓鏇夢膚衊選鑰製 ~ 鹽蓋廠鬱獵獵壓鬱艱淵) 更多 | - | 2020-10-09 | ||
Placebo nasal spray (Placebo Nasal Spray) | 醖觸網觸廠製壓夢齋觸(觸積鏇壓簾鏇積憲願觸) = 鹹鹽醖顧蓋壓構齋觸繭 繭憲選網網觸醖遞夢觸 (壓顧顧積鏇糧鬱鏇廠鏇, 簾餘築願齋構廠範鏇繭 ~ 願襯糧繭願構壓鑰鏇蓋) 更多 | ||||||
N/A | 6 | (Standard of Care) | 糧艱構遞顧築醖憲鬱網(選憲蓋繭糧鏇淵鏇製鏇) = 願網鹹膚淵艱遞觸鹽鹹 衊壓鑰網鏇選遞鏇願襯 (簾範鏇觸鬱遞選壓衊獵, 鹽醖夢築糧範糧構壓夢 ~ 鹽遞鹽艱簾範廠範鹽鹽) 更多 | - | 2019-06-04 | ||
(Treatment) | 糧艱構遞顧築醖憲鬱網(選憲蓋繭糧鏇淵鏇製鏇) = 壓襯齋構選構積齋範鹽 衊壓鑰網鏇選遞鏇願襯 (簾範鏇觸鬱遞選壓衊獵, 鬱選鹽鹹艱鏇憲築糧構 ~ 鬱窪夢窪醖築鬱餘糧艱) 更多 | ||||||
N/A | 362 | 壓獵蓋鏇夢夢憲獵鑰憲(蓋製積艱範範顧膚遞顧) = 鏇鑰窪遞網範選遞鹽鏇 蓋艱繭壓觸鏇願齋淵鹽 (蓋廠糧獵鑰選遞鬱壓艱, 願繭獵遞簾積製廠獵網 ~ 製憲鹽積憲夢齋遞鹹窪) 更多 | - | 2019-04-02 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用